New data from COU-AA-302 trial of Zytiga (abiraterone acetate) shows increased overall survival versus prednisone alone for prostate cancer- Janssen Biotech

Data presented at the European Association of Urology (EAU) 2016 Congress in Munich, Germany, demonstrated that in the COU-AA-302 trial, Zytiga (abiraterone acetate) from Janssen Biotech increased overall survival (OS) to 53.6 months versus the 41.8 months achieved by patients treated with prednisone alone. This benefit was shown to be 4.4 months longer than previously reported for the combination in the final analysis of the COU-AA-302 trial in 2014.

The post-hoc analysis divided patients into two groups to identify which group experienced a greater treatment benefit. The patients in group 1 were in an earlier, less advanced and less symptomatic stage of the disease, while those in group 2 were in a later, more advanced and more symptomatic stage of the disease. While both groups experienced an OS benefit when treated with the abiraterone/prednisone combination, the benefit was greater in the men with early-stage disease. The latter stage group’s overall survival was 2.8 months greater than patients treated with prednisone only.

In addition to OS benefit, the post-hoc analysis data also revealed that both groups showed improvement in disease progression, cancer-related pain and treatment duration when treated with the combination. Time to chemotherapy use was increased by 12.7 months in group 1 and 8.8 months in group 2.